Published: December 2008
Pages: 80
Price (USD): $1,100/single user PDF licence
Report Summary
"Booming Global Obesity Drug Market", our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it's expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.
The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi's Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.
The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.
Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China's obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.
Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.
Our report provides forecast on
Global obesity market
Xenical revenue
Meridia revenue
Alli revenue
Global prevalence of obesity
Prevalence of obesity in major developed and emerging markets
Profiling on Key Players
This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.
Report Outline
1. Analyst View
2. The Global Obesity Epidemic
2.1 Defining Obesity
2.2 Prevalence of Obesity
2.3 The Cost of Obesity
2.4 Obesity is Linked to Higher Rates of Chronic Conditions
2.5 Obese Spend Significantly Higher on Healthcare
3. Available Weight-loss Techniques & Products
3.1 Weight-loss Surgery
3.2 Liposuction
3.3 Weight-loss Foods & Drinks
3.4 Diet Centres
3.5 Weight-loss Drugs
4. Obesity Drugs Market
4.1 Market Opportunity Assessment
4.2 Key Weight-loss Drugs
4.2.1 Alli
4.2.1.1 Market Performance
4.2.1.2 Critical Success & Risk Factors
4.2.2 Xenical
4.2.2.1 Market Performance
4.2.2.2 Critical Success & Risk Factors
4.2.3 Acomplia
4.2.3.1 Market Performance
4.2.3.2 Critical Success & Risk Factors
4.2.4 Meridia
4.2.4.1 Market Performance
4.2.4.2 Critical Success & Risk Factors
4.3 Weight-loss Drugs under Clinical Trials
5. Obesity in Developed Markets - A Brief Profile
5.1 US
5.2 Japan
5.3 Germany
5.4 UK
5.5 France
5.6 Italy
5.7 Spain
6. Obesity in Emerging Markets - A Brief Profile
6.1 Russia
6.2 India
6.3 Brazil
6.4 China
7. Critical Success Factors
7.1 Expanding Waistlines
7.2 High Unmet Needs
7.3 Self-Consciousness & Fulfillment
7.4 Strong Pipeline
8. Critical Risk Factors
8.1 High Failure Rate
8.2 High Consumer Demand
8.3 Reimbursement Issues
8.4 Side Effects
9. Key Company Profiles
9.1 Abbott Laboratories
9.2 Roche Holding Ltd
9.3 Sanofi-Aventis
9.4 GlaxoSmithKline plc
9.5 Pfizer Inc.
Figures
Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012
Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012
Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%)
Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking
Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%)
Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007
Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F
Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007
Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F
Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F
Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008
Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F
Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F
Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F
Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006
Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006
Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006
Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006
Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches
Tables
Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI
Table 3-1: US - Liposuction Statistics (2007)
Table 4-1: Alli - Success & Risk Factor Analysis
Table 4-2: Xenical - Success & Risk Factor Analysis
Table 4-3: Acomplia - Success & Risk Factor Analysis
Table 4-4: Meridia - Success & Risk Factor Analysis
Table 4-5: Obesity Drugs in Phase-III Clinical Trials
Table 4-6: Obesity Drugs in Phase-II Clinical Trials
Table 4-7: Obesity Drugs in Phase-I Clinical Trials
Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F)
Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs
Table 9-1: Abbott Laboratories - Strengths & Weaknesses
Table 9-2: Roche Holding Ltd - Strengths & Weaknesses
Table 9-3: Sanofi-Aventis - Strengths & Weaknesses
Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses
Table 9-5: Pfizer Inc. - Strengths & Weaknesses
